# Edoxaban for the Treatment of Coagulopathy in Patients With Active Cancer and Acute Ischemic Stroke: a Pilot Study. (ENCHASE Study)

> **NCT03570281** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Samsung Medical Center** · enrollment: 40 (estimated)

## Conditions studied

- Correction of Cancer-related Coagulopathy With Novel Oral Anticoagulant (Edoxaban)

## Interventions

- **DRUG:** Edoxaban
- **DRUG:** Enoxaparin

## Key facts

- **NCT ID:** NCT03570281
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-06-15
- **Primary completion:** 2020-05-31
- **Final completion:** 2020-11-30
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2018-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03570281

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03570281, "Edoxaban for the Treatment of Coagulopathy in Patients With Active Cancer and Acute Ischemic Stroke: a Pilot Study. (ENCHASE Study)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03570281. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*